TABLE 5.
Urinary 8-hydroxydeoxyguanosine (8-OHdG) concentrations (in ng/mg creatinine) indicate an interaction between MAT1A haplotypes and plasma vitamin B-6 concentration in the Boston Puerto Rican Health Study
| Vitamin B-6 <55 nmol/L |
Vitamin B-6 ≥55 nmol/L |
||||||
| Haplotype1 | Frequency | Carrier | Noncarrier | P value2 | Carrier | Noncarrier | P value2 |
| G-G-G | 0.37 | 134.5 (6.2)3 | 140.5 (6.7) | 0.465 | 124.1 (8.9) | 118.0 (9.5) | 0.734 |
| A-G-A | 0.27 | 144.8 (6.8) | 132.3 (6.1) | 0.118 | 125.5 (9.5) | 118.6 (8.9) | 0.177 |
| 4 | 0.26 | 145.8 (6.6) | 130.2 (6.2) | 0.036 | 113.3 (9.3) | 128.5 (9.0) | 0.020 |
| A-G-G | 0.07 | 128.6 (11.1) | 138.0 (5.7) | 0.378 | 125.7 (14.6) | 121.1 (8.3) | 0.759 |
| G-G-A | 0.03 | 125.9 (13.4) | 137.9 (5.7) | 0.669 | 114.3 (19.2) | 122.0 (8.3) | 0.993 |
MAT1A haplotypes were estimated based on 3 single nucleotide polymorphisms in the following order: i15173, 3U1510, and d18777.
P values were calculated by linear regression models and adjusted for MTHFR genotype, age, sex, BMI, smoking, alcohol use, physical activity, medication use for depression and type 2 diabetes, population admixture, and plasma concentrations of vitamin B-12, folate, and creatinine.
Mean; SE in parentheses (all such values).
The interaction between haplotype A-A-G and vitamin B-6 was highly significant at P = 0.0004, whereas there was no significant interaction between other haplotypes and vitamin B-6.